Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements

British Journal of Ophthalmology

Volumn 93, Issue 8, 2009, Pages 1027-1032

  Shah, A R ^a   Del Priore, L V ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOVEA CENTRALIS; HUMANS; INJECTIONS; MACULA LUTEA; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 68049100005     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.149674     Document Type: Article

References (24)

1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
2. Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 1993;100:1519-1535
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 2006;355:1419-1431 (Pubitemid 44511557)
4. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390 (Pubitemid 44197628)
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 2006;355:1432-1444 (Pubitemid 44511558)
6. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823 (Pubitemid 351261238)
7. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372e5.
8. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9. (Pubitemid 43946791)
9. Adan A, Navarro M, Casaroli-Marano RP, et al. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 2007;245:1873-1875 (Pubitemid 350154024)
10. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444 (Pubitemid 46624283)
11. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284 (Pubitemid 44318180)
12. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056 (Pubitemid 44853889)
13. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-750 (Pubitemid 46483714)
14. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859
15. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733 (Pubitemid 40270359)
16. Algvere PV, Steen B, Seregard S, et al. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol Scand 2008;86:482-489
17. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:4300-4307 (Pubitemid 351261062)
18. Thompson D. VA testing in optometric practice. Part 2: Newer chart designs. Optom Today 2005 May: 22-24 http://www.otmagazine.co.uk/articles/docs/ fdaa91e06ebe44f10bc2ccef (accessed 15 Jan 2009).
19. Carl Zeiss Meditec. Stratus OCT Software Version 4.0 Booklet, Zeiss Manual, 2006. Carl Zeiss Meditec, Dublin. http://www.meditec.zeiss.com/ 88256DE3007B916B/0/ C26634D0CFF04511882571B1005DECFD/$file/stratusoct-en. pdf (accessed 14 May 2009).
20. Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-1875 (Pubitemid 47483925)
21. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182
22. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-1246 (Pubitemid 47344908)
23. Tatlipinar S, Shah SM, Campochiaro PA, et al. Intraobserver repeatability of automated versus adjusted optical coherence tomography measurements in patients with neovascular age-related macular degeneration. Ophthalmologica 2007;221:227-232 (Pubitemid 46956799)
24. Campbell RJ, Coupland SG, Buhrmann, et al. Optimal optical coherence tomography-based measures in the diagnosis of clinically significant macular edema: retinal volume vs. focal thickness. Arch Ophthalmol 2007;125:619-623